Citadel Advisors’s NewAmsterdam Pharma NAMS Stock Holding History

Citadel Advisors’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$22.8M	Buy	712,064 +76,817	+12%	+$2.5M	﹤0.01%	2172
2025 Q4	$22.3M	Buy	635,247 +428,786	+208%	+$15.6M	﹤0.01%	2227
2025 Q3	$5.87M	Sell	206,461 -113,682	-36%	-$2.73M	﹤0.01%	4061
2025 Q2	$5.8M	Sell	320,143 -361,790	-53%	-$6.6M	﹤0.01%	3859
2025 Q1	$14M	Sell	681,933 -293,898	-30%	-$6.53M	﹤0.01%	2446
2024 Q4	$25.1M	Buy	975,831 +453,366	+87%	+$9.63M	﹤0.01%	1921
2024 Q3	$8.67M	Buy	522,465 +308,311	+144%	+$5.33M	﹤0.01%	3140
2024 Q2	$4.11M	Sell	214,154 -240,180	-53%	-$4.82M	﹤0.01%	4059
2024 Q1	$10.7M	Buy	454,334 +433,288	+2,059%	+$8.79M	﹤0.01%	2857
2023 Q4	$235K	Sell	21,046 -10,351	-33%	-$94.8K	﹤0.01%	9632
2023 Q3	$290K	Buy	+31,397	New	+$340K	﹤0.01%	9242

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Citadel Advisors's NAMS Position: Q1 2026 in Review

Citadel Advisors increased its NewAmsterdam Pharma (NAMS) stake by 12% in Q1 2026, buying an estimated $2.5M and bringing the position to 712,064 shares worth $22.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2172.

Citadel Advisors first reported a position in NAMS in Q3 2023 and has held it in 11 quarters since. The position peaked at $25.1M in Q4 2024. 170 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

Citadel Advisors held 712,064 shares of NewAmsterdam Pharma worth $22.8M as of Q1 2026.
Citadel Advisors bought 76,817 NewAmsterdam Pharma shares in Q1 2026, an estimated $2.5M.
NewAmsterdam Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2172 holding.
Citadel Advisors first reported a position in NewAmsterdam Pharma in Q3 2023 and has held it in 11 quarters since.
Citadel Advisors's NewAmsterdam Pharma position peaked at $25.1M in Q4 2024.
170 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.